AFFILIATIONS
1 Inserm U1310, Villejuif, France
2 Inserm U1310, Villejuif, France
3 Inserm U1310, Villejuif, France
4 Center for IPSC Therapies CITHERA, Evry, France, Inserm U1310, Villejuif, France
5 Center for IPSC Therapies CITHERA, Evry, France, Inserm U1310, Villejuif, France
6 Center for IPSC Therapies CITHERA, Evry, France, Inserm U1310, Villejuif, France
7 Center for IPSC Therapies CITHERA, Evry, France, Inserm U1310, Villejuif, France
ABSTRACT
Introduction
NMD is an RNA surveillance pathway that degrades aberrant transcripts, limiting the expression of mutated and aberrantly spliced RNAs that could otherwise generate tumor-associated antigens. SMG1 is a serine protein kinase which plays a major role in in this pathway by degrading incomplete RNA transcripts. Cancer cells frequently exploit NMD to evade immune surveillance. KVS0001 is a novel inhibitor of SMG1 with previously demonstrated anti-tumor activity through induction of immune responses. However, the molecular targets underlying this immune activation remain unknown. In the context of CML, the discovery of novel immunotherapeutic targets is of interest both for eradicating CML stem cells and for designing novel cell therapies in patients with advanced disease. Patient-derived CML IPSCs allow modeling different phases of the disease by generating differentiated leukemic progeny in vitro in 2-3 weeks. However, when these iPSCs are modified by in vitro mutagenesis using N-ethyl-N-nitroso-urea (ENU), they give rise to undifferentiated blast cells (BC), mimicking the acute phase of the disease. Here we used this unique experimental tool to identify leukemia-associated transcripts unmasked by SMG1 inhibition, with the goal of discovering disease-specific targets for both chronic phase (CP) and blast crisis (BC) phase of CML.
CML IPSCs and their ENU-mutagenized counterparts along with normal iPSCs were treated with KVS0001 to pharmacologically inhibit NMD at established doses, followed by RNA sequencing of both cell populations. The latter was performed followed by differential expression analysis of leukemic versus normal IPSCs. Leukemia-selective transcripts induced following treatment were prioritized based on tumor-restricted expression (GTEx; <2 TPM or absent in normal adult tissues), predicted MHC class I peptide presentation and protein annotation. The expression of selected candidate genes was further assessed by RT-qPCR in primary CML samples and healthy hematopoietic controls (cord blood cells).
Results
Preliminary in silico evaluation of the transcriptome data of CML iPSC lines allowed the identification of potential target transcripts of NMD in CML such as GADD45a, DDIT3, ATF3. RT-qPCR validation confirmed their accumulation following SMG1 inhibition, demonstrating effective pharmacological inhibition of NMD. We subsequently preformed global RNA-seq analysis of the CML versus control iPSCs with and without SMG1 inhibition. This analysis identified 1,393 transcripts selectively upregulated in CML IPSCs following treatment but not in the healthy donor derived IPSCs. Of these, 248 transcripts exhibited tumor-restricted expression, with minimal or absent expression across normal adult cells. Functional annotation identified seven transcripts encoding predicted transmembrane proteins, representing promising candidates for cell-surface targeting approaches. To evaluate the relevance of these findings in primary disease samples, CML blast cells of patients were treated with and without SMG1 inhibitor and compared to cord blood cells treated in the same condition. RT-qPCR analysis confirmed the significant overexpression of several of these transcripts in CML blast cells as compared to cord blood cells. Of the CML-restricted transcripts which have been found to increase upon NMD inhibition, NetMHC analysis predicted 2,306 MHC class I-binding peptides, highlighting a substantial reservoir of candidate neoantigens exposed by NMD inhibition. In parallel, SMG1 inhibition uncovered eight novel transposable-element derived transcripts, several of which were also predicted to generate MHC class I-binding neoantigens. Further studies using a larger cohort of CML patients are underway. Collectively, these findings reveal a previously concealed and therapeutically actionable repertoire of CML-associated transcripts exposed by NMD inhibition.
Conclusions
Pharmacological inhibition of SMG1 in the context CML iPSCs uncovered a previously hidden repertoire of potential therapeutic targets for CP and BC-CML. After integrating transcriptomic profiling with tumor-specificity filtering, protein annotation and neoantigen prediction, experiments underway aim to identify candidate proteins with potential for CAR-T cell therapy targets in BC and tumor-specific neoantigens that may be exploited for vaccine-based immunotherapies in CP patients resistant to tyrosine kinase inhibitors.
DISCLOSURES
Shanelle Mullany, PhD: No relevant conflicts of interest to declare.